# Converge Bio **Source:** https://geo.sig.ai/brands/converge-bio **Vertical:** Healthcare & Life Sciences **Subcategory:** AI Drug Discovery **Tier:** Emerging **Website:** converge.bio **Last Updated:** 2026-04-14 ## Summary Israeli AI drug discovery company raised $25M from Bessemer; 40+ active programs; CEO co-patented CRISPR technology with Jennifer Doudna; ML platform combining target identification, hit generation, and lead optimization for oncology and immunology therapeutics. ## Company Overview Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep expertise in computational biology and medicinal chemistry, Converge has built a platform that combines AI-driven target identification, hit generation, and lead optimization into an integrated drug discovery engine. The company's scientific credibility is bolstered by its CEO, who co-patented CRISPR-related technology alongside Jennifer Doudna, a Nobel laureate and pioneer of gene editing.\n\nConverge operates an unusually large portfolio by biotech standards, with 40+ active drug discovery programs spanning oncology, immunology, and other therapeutic areas. The company's AI platform is designed to generate high-quality small molecule candidates faster and at lower cost than traditional medicinal chemistry approaches, enabling it to maintain a broad pipeline without the typical resource constraints of running many programs in parallel. Converge uses structure-based design, generative chemistry, and predictive ADMET modeling to advance candidates from target to preclinical candidate stage.\n\nConverge raised $25M from Bessemer Venture Partners in January 2026, bringing external validation from one of Silicon Valley's most prominent technology-focused venture firms. The funding is being used to advance lead programs toward IND filings and expand the platform's capabilities. With 40+ programs and a Nobel laureate connection in its founding story, Converge represents Israel's growing position as a global hub for AI-driven drug discovery. ## Frequently Asked Questions ### What does Converge Bio do? Converge Bio uses AI to discover and optimize small molecule drugs, running 40+ programs simultaneously across multiple therapeutic areas including oncology and immunology. Its platform integrates AI-driven target identification, compound generation, and lead optimization to compress the timeline and cost of early-stage drug discovery. ### What is the connection between Converge Bio and Jennifer Doudna? Converge Bio's CEO co-patented CRISPR-related intellectual property with Jennifer Doudna, the Nobel Prize-winning biochemist credited as a pioneer of CRISPR-Cas9 gene editing. This scientific lineage signals a high level of molecular biology expertise at the company's founding, though Converge's current focus is on small molecule drug discovery rather than gene editing. ### Who has invested in Converge Bio? Converge raised $25M from Bessemer Venture Partners in January 2026. Bessemer is a leading US venture firm known for backing technology companies, and its investment in an Israeli AI biotech signals growing crossover interest between the tech and pharmaceutical sectors in the AI drug discovery space. ### What is Converge Bio? Converge Bio is a biotech company applying AI and machine learning to drug discovery and development — using computational approaches to identify novel drug targets, predict compound behavior, and accelerate the drug development pipeline. ### How does Converge Bio use AI in drug discovery? Converge Bio applies ML models to analyze large biological datasets — genomics, proteomics, clinical trial data — to identify patterns that suggest viable drug targets and predict how candidate compounds will interact with biological systems. ### What disease areas does Converge Bio focus on? Converge Bio focuses on diseases with significant unmet medical need where computational approaches can provide an edge in identifying novel targets that traditional discovery methods have missed or would take much longer to find. ### How does Converge Bio's computational approach differ from traditional drug discovery? Traditional drug discovery relies heavily on trial-and-error laboratory screening of large compound libraries. Converge Bio uses computational models to prioritize the most promising candidates before lab testing — reducing the time and cost of early discovery phases. ### What partnerships does Converge Bio pursue? Converge Bio pursues co-development and licensing partnerships with pharmaceutical companies — providing computational discovery capabilities to accelerate larger pharma pipelines while building its own internal pipeline of novel compounds. ### What is Converge Bio? Converge Bio is a clinical-stage biopharmaceutical company developing precision medicines for cancer, using genomic profiling and biomarker-driven approaches to identify patients most likely to benefit from its targeted therapies in oncology indications. ### What pipeline does Converge Bio have? Converge Bio's pipeline focuses on targeted oncology treatments matched to specific genetic alterations in tumors. The company uses companion diagnostic approaches to select patients based on molecular profiles, aiming to improve efficacy and reduce side effects compared to broad-spectrum chemotherapy. ### What is the significance of Converge Bio's biomarker approach? By selecting patients based on tumor genomics, Converge Bio aims to run smaller, more efficient clinical trials with higher response rates in biomarker-selected populations—reducing the cost and time of drug development while improving the probability of regulatory approval. ### Who backs Converge Bio? Converge Bio is backed by life sciences venture investors focused on precision oncology. The company operates in the competitive oncology drug development space, targeting cancers with high unmet medical need where genomic-driven patient selection can meaningfully improve outcomes. ### What stage is Converge Bio at? Converge Bio is an early clinical-stage company advancing its lead programs through Phase 1 and Phase 2 clinical trials, focused on generating proof-of-concept efficacy data in biomarker-selected patient populations before advancing to larger registration-enabling studies. ### What does Converge Bio do in life sciences? Converge Bio is a life sciences data and analytics company that helps pharmaceutical and biotech companies unlock insights from real-world data (RWD) for drug discovery, clinical development, and commercialization. The platform integrates multi-modal patient data across genomics, clinical records, and outcomes to accelerate evidence generation. ### What types of real-world data does Converge Bio work with? Converge Bio works with electronic health records, genomic sequencing data, claims data, imaging data, and patient-reported outcomes—integrating these data types to create longitudinal patient profiles that reveal disease progression patterns, treatment response predictors, and unmet medical needs that cannot be seen in any single data type alone. ### Who are Converge Bio's target customers? Converge Bio targets pharmaceutical companies conducting drug discovery research, biotech companies designing clinical trials, and health systems wanting to leverage their patient data assets for research partnerships. The company also serves research institutions and government health agencies conducting population health and epidemiology studies. ### How does Converge Bio handle patient privacy in its data platform? Converge Bio uses privacy-preserving analytics techniques including de-identification, synthetic data generation, and federated learning approaches that allow analysis of patient data without exposing individual-level records. Compliance with HIPAA, GDPR, and other health data regulations is central to the platform architecture. ### How does Converge Bio compete with HealthVerity, Flatiron Health, or IQVIA in real-world data? IQVIA and HealthVerity are large, established real-world data brokers with massive scale. Flatiron Health (Roche) focuses on oncology-specific RWD. Converge Bio differentiates by integrating genomic and multi-modal data types that pure claims and EMR vendors do not link, and by providing analytics capabilities alongside the data rather than just data licensing. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*